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Abstract
During hematopoiesis, transcriptional programs are essential for the commitment and differ-
entiation of progenitors into the different blood lineages. GATA1 is a transcription factor
expressed in several hematopoietic lineages and essential for proper erythropoiesis and
megakaryopoiesis. Megakaryocyte-specific genes, such asGP1BA, are known to be
directly regulated by GATA1. Mutations in GATA1 can lead to dyserythropoietic anemia and
pseudo gray-platelet syndrome. Selective loss of Gata1 expression in adult mice results in
macrothrombocytopenia with platelet dysfunction, characterized by an excess of immature
megakaryocytes. To specifically analyze the impact of Gata1 loss in mature committed
megakaryocytes, we generated Gata1-Lox|Pf4-Cre mice (Gata1cKOMK). Consistent with
previous findings, Gata1cKOMK mice are macrothrombocytopenic with platelet dysfunction.
Supporting this notion we demonstrate that Gata1 regulates directly the transcription of Syk,
a tyrosine kinase that functions downstream of Clec2 and GPVI receptors in megakaryo-
cytes and platelets. Furthermore, we show that Gata1cKOMK mice display an additional
aberrant megakaryocyte differentiation stage. Interestingly, these mice present a misbal-
ance of the multipotent progenitor compartment and the erythroid lineage, which translates
into compensatory stress erythropoiesis and splenomegaly. Despite the severe thrombocy-
topenia, Gata1cKOMK mice display a mild reduction of TPO plasma levels, and Gata1cK-
OMK megakaryocytes show a mild increase in Pf4 mRNA levels; such a misbalance might
be behind the general hematopoietic defects observed, affecting locally normal TPO and
Pf4 levels at hematopoietic stem cell niches.
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Introduction
GATA1 is a critical transcription factor for the differentiation of several hematopoietic lineages
[1]. It is expressed in megakaryocytes [2], primitive and definitive erythroid cells [3], eosino-
phils [4], mast cells [5], dendritic cells [6] and Sertoli cells of the testis [7]. It belongs to the
GATA family of zinc-finger transcription factors, which recognize the W(A/T)GATAR(A/G)
DNAmotif, and is located on the X-chromosome [8].
GATA1 regulates the transcription of lineage-specific genes contributing to differentiation,
cell cycle regulation and survival of the hematopoietic lineages that express it [9–12]. In addi-
tion, it regulates the expression of target genes either by repressing or activating their transcrip-
tion, depending on the transcription factor complex where it acts [13]. As an additional
dimension of regulation, timely GATA1 levels during lineage commitment and differentiation
are crucial for its proper action as master transcription regulator, and reciprocal regulation
with the other hematopoietic GATA factors, such as GATA2 and GATA3, during lineage com-
mitment and specification needs to be properly orchestrated [14–18].
In humans, several mutations affecting the GATA1 gene have been described, which lead to
a broad spectrum of defects, including X-linked thrombocytopenia (XLT), X-linked thrombo-
cytopenia with thalassemia (XLTT) and transient myeloproliferative disorder (TMD) [19, 20].
All disorders have in common mutations mostly located in the amino (N)-zinc finger region of
GATA1, which might influence either DNA binding directly and/or the interaction with Friend
of Gata1 (FOG1), leading to macrothrombocytopenia. Besides these deficiencies, patients with
Down syndrome are more likely to develop an acquired, i.e. somatic, GATA1mutation leading
to a truncated form of GATA1 (GATA1s). This short GATA1 isoform increases the possibility
to develop acute megakaryoblastic leukemia (AMKL) [21].
Gata1 knockout mice die around day E10.5 of gestation due to severe anemia [22] and con-
ditional ablation of Gata1 has shown its requirement in the erythro-megakaryocytic lineages in
adult mice [23]. Mice with targeted mutations on the Gata1 promoter affecting its expression,
such as Gata-1.05/X female mice and ΔneoΔHS mice, display severe macrothrombocytopenia,
an increased proliferation of megakaryocytes, and platelets with a defective response to colla-
gen and vWF [2, 24]. From these studies, megakaryocytic Gata1 target genes were unveiled,
such as GP1BA, GP1BB and PF4 [25]. However, these mouse models are not tissue/lineage spe-
cific or display downregulation of Gata1 instead of complete loss.
The generation of tissue specific conditional mouse model tools, i.e. Pf4-Cre mice, makes
possible the study of Gata1 loss specifically in the megakaryocytic lineage [26]. We have gener-
ated megakaryocyte-specific Gata1-Lox|Pf4-Cre mice in order to study not only the direct con-
sequences of Gata1 depletion in committed megakaryocytes but its repercussion on the general
hematopoietic compartment. Consistent with previous findings, late ablation of Gata1 in the
megakaryocytic lineage resulted in macrothrombocytopenia and platelets that are functionally
impaired. Some of the defective responses in platelets were due to a defect on receptor expres-
sion, i.e. integrin β1, vWF-R. However, other defects appeared to happen downstream other
receptors, i.e. Clec2 and GPVI. We have identified Syk, a pivotal tyrosine kinase that functions
downstream of Clec2 and GPVI receptors in megakaryocytes and platelets, as a bona fide
Gata1 target. Interestingly, we describe an additional aberrant megakaryocyte differentiation
stage in bone marrow and spleen. Furthermore, we show that these mice, and most likely due
to the platelet production defect and concomitant stress megakaryopoiesis caused by Gata1
loss in the megakaryocytic lineage, display misbalance of their multipotent progenitor and ery-
throid compartments and present with compensatory extramedullary hematopoiesis with
splenomegaly.
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Materials and Methods
Mice
Gata1-lox mice [27] were crossed with Pf4-Cre mice [26] and maintained in the Dutch Cancer
Center (NKI) animal facility under specific pathogen-free conditions and following the institu-
tional ethical committee guidelines.
Syk-lox animals (Syktm1.2Tara) [28], obtained from Professor Alexander Tarakhovsky (The
Rockefeller University, New York, USA), were crossed to Pf4-Cre mice [26]. The genotyping
was carried out by using allele-specific PCR. The efficacy and specificity of cell-specific Syk
deletion was tested on cell lysates by Western blotting (data not shown). The experimental ani-
mals were kept in individually sterile ventilated cages (Tecniplast) under specific pathogen-free
conditions until use, when they were transferred to the conventional facility. Animal experi-
ments made on these cell-specific Syk-deleted mice were approved by the Animal Experimen-
tation Review Board of the Semmelweis University.
Mice were anesthetized with isofluoran, bled by heart puncture, euthanized by cervical dis-
location and dissected for bone marrow and spleen collection.
Blood analysis and platelet functional assays
Blood was drawn by heart puncture and collected in heparin-coated vials (Sarstedt, Nϋm-
brecht, Germany). Blood parameters were determined on a scil Vet abc Plus+. FCA was per-
formed as described [29]. Platelet adhesion to collagen at physiological shear rate was
performed as described [30]. In brief, whole blood was reconstituted to the same platelet con-
centration amongst genotypes, and was perfused over collagen-coated slides (Horm-Collagen
type I, 100 μg/ml) at a shear rate of 1300s-1. After labeling platelets with CD61-FITC conju-
gated antibody, photos were taken at 200x magnification with an EVOS microscope. Coverage
of fluorescence was quantified with ImageJ software.
Flow cytometry
Platelets or bone marrow single cell suspensions were stained for flow cytometry analysis as
previously described [30, 31]. Antibodies used were: CD61-FITC, CD41-PE, Sca1-PECy7,
CD34-FITC, Lin-cocktail-APC, CD16/CD32-PE, cKit-PerCP, CD71-FITC, Ter119-V405 (BD
Pharmingen, Oxford, United Kingdom), Clec2–FITC (AbD Serotec, Kidlington, United King-
dom), CD42a-FITC, CD42b-DL649, CD42c-FITC (Emfret, Wurzburg, Germany), GPVI-PE
(R&D, Abingdon, United Kingdom), CD9-PE, CD31-PECy7 (Abcam, Cambridge United
Kingdom) and CD49b-PB (BioLegend, San Diego, CA).
Mouse plasma TPO ELISA
TPO levels were measured on the plasma of Gata1cKOMK and WTlox mice with a Quantikine
Mouse Thrombopoietin ELISA Kit (R&D Systems), following the manufacturer´s guidelines.
Bone marrow-derived megakaryocyte cultures
Megakaryocyte cultures were performed as previously described [30, 31].
RNA
CD61+CD41+CD49b+ cells were sorted from megakaryocyte cultures on a FACS ARIA (BD
Bioscience) and used for RNA extraction using Trizol (Ambion, Life Technologies). cDNA was
prepared from 1μg RNA with Superscript III first strand (Invitrogen). Expression levels of
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mRNAs were analyzed by quantitative real-time PCR (qPCR) using SYBR green on an Applied
Biosystems StepOne RT-qPCR system (Life Technologies). All reactions were performed in
triplo.
Gene expression levels were calculated with the 2-ΔCT method [32]. Target gene expression
was normalized to Gapdh expression. Primers used were:
Gata1 5’-CAGTCCTTTCTTCTCTCCCAC-3’ and 5’-GCTCCACAGTTCACACACT-3’;
PU.1 5’-TCTTCACCTCGCCTGTCTT-3’ and 5’-TCCAGTTCTCGTCCAAGCA-3’;
Syk 5’-TCACAACAGGAAGGCACAC-3’ and 5’-GAGTGGTAATGGCAGAGGTC-3’;
Pf4 5’-CTGCGGTGTTTCGAGGCCTCC-3’ and 5’-accagcgctggtgacagcaa-3’;
Gapdh 5’-CCTGCCAAGTATGATGACAT-3’ and 5’-GTCCTCAGTGTAGCCCAAG-3’.
Protein
Approximately 109 platelets were lysed in 500 μl RIPA buffer (150 mMNaCl, 1% NP-40, 0.5%
Deoxycolate, 0.1% SDS, 50 mM Tris HCL, pH 7.5). Proteins were separated by SDS-PAGE gel
electrophoresis and transferred to PVDF membranes and incubated following standard proce-
dures. Antibodies used were Anti-Gata1 (sc-265, Santa Cruz), Anti-Syk (sc-573, Santa Cruz),
Anti-Gapdh (MAB374, Merck Millipore), and secondary antibodies IRDye 680 goat anti-
mouse IgG and IRDye 800CW donkey anti-mouse IgG (926–32220 and 926–32212, respec-
tively, LI-COR Biosciences). Western blot membranes were quantified using Odyssey LI-COR
Imaging system.
Chromatin Immunoprecipitation (ChIP)
Chromatin Immunoprecipitations were performed as previously described [33] using anti-
Gata1 antibody (ab11963, Abcam) and protein A magnetic beads (10002D, Life Technologies).
Enrichment of a DNA region of interest was measured by qPCR. Primers used were:
Syk GATA positive (+) amplicon:
5’-TCACAACAGGAAGGCACAC-3’ and 5’-GAGTGGTAATGGCAGAGGTC-3’;
Gp1ba GATA positive (+) amplicon:
5’-GCTGATAAGAGCCTTTGCC-3’ and 5’-GGGAGGAAATGACAACCTG-3;
Cd9 GATA negative (-) amplicon:
5’-ACCGTGCTCAACTAAGTGCG-3’ and 5’-AGATTCCCGAGGCAAGTCTG-3’.
Statistical Analysis
We represent average and standard error of the mean (SEM) of at least three mice per genotype
or experiments unless otherwise indicated. We applied two-tailed Student’s t-tests to calculate
statistical significance.
Results
To investigate the role of Gata1 in late megakaryopoiesis, Gata1-lox|Pf4-Cre mice were gener-
ated [26, 27]. From now on we refer to these mice as Gata1cKOMK, and to control Gata1-lox
littermates as WTlox. To quantify Gata1 reduction in Gata1cKOMK mice, Gata1mRNA levels
were quantified in cultured bone marrow megakaryocytes. On average, an 80% reduction of
Gata1 in megakaryocytes was observed, while the levels of transcription factor PU.1 (Spi1)
were not affected (Fig 1a). Consistent with previous reports [2, 24, 25], Gata1cKOMK mice suf-
fer from severe macrothrombocytopenia, while the red and white blood cell numbers are unaf-
fected (Fig 1b). Furthermore, platelets were impaired to adhere and to form thrombi over
collagen-coated slides at physiological shear rate (Fig 1c).
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Malfunction of Gata1cKOMK platelets
It has been previously reported that platelets derived from ΔneoΔHS mice are dysfunctional
[34], and consistently, we observed a dramatic defect of Gata1cKOMK platelets using perfusion
assay (Fig 1c). To increase knowledge on the platelet dysfunction caused by Gata1 loss in
Fig 1. Gata1cKOMKmice display severemacrothrombocytopenia and platelet dysfuncion while other
blood cell counts are unaffected. (a)Gata1 and PU.1 (Spi1) mRNA expression levels in Gata1cKOMK and
WTlox cultured megakaryocytes. PU.1 (Spi1) levels are normal in Gata1cKOMK mice. RFE, relative fold
enrichment. (b) Blood parameters of Gata1cKOMK andWTlox mice at 8–12 weeks of age. PLT, platelets;
MPV, mean platelet volume; RBC, red blood cells; WBC, white blood cells. (c) Platelet adhesion to collagen
under physiological shear rate. Whole blood fromWTlox and Gata1cKOMK mice was perfused over collagen-
coated slides. Adhered platelets were visualized with CD61-FITC conjugated antibody, and
immunofluorescence coverage of slides was quantified, and is represented.
doi:10.1371/journal.pone.0154342.g001
Gata1 Regulates Megakaryocyte Syk Transcription
PLOS ONE | DOI:10.1371/journal.pone.0154342 May 6, 2016 5 / 17
megakaryocytes in Gata1cKOMK mice, we measured platelet aggregation using FCA, which
allows the study of the contribution of single receptors to the aggregation process [29]. We
observed that upon stimulation with aggretin (Clec2 agonist), collagen (GPVI and α2ß1 ago-
nist), convulxin (GPVI agonist), and botrocetin (GPIb/V/IX agonist), platelet aggregation
responses were severely reduced, whereas responses were only mildly affected when stimulated
with PMA (PKC agonist that triggers αIIbß3 integrin-dependent aggregation; Fig 2a). The
reduced aggregation capacity upon stimulation with botrocetin and collagen could be
Fig 2. Functional analysis of platelets fromGata1cKOMK and SykcKOMK mice show overlapping defects. (a) Flow
cytometry-based platelet aggregation assay (FCA) shows the aggregation capacity of platelets when stimulated with
different agonists. Gata1cKOMK andWTlox platelets were studied. PMA, phorbol myristate acid; Agg, aggretin; Botro.
Botrocetin; Coll, collagen; CVX, convulxin. (b) MFI of receptors expressed on Gata1cKOMKplatelets, relative expression of a
given receptor in WTlox platelets was set to 100. For clarification: CD61 (Itgb3), CD41 (Itga2b), CD42a (GPIX), CD42b
(Gp1ba), CD42c (Gp1bb), CD49b (Itga2). (c) Flow cytometry-based platelet aggregation assay (FCA) shows the
aggregation capacity of SykcKOMK andWTlox platelets when stimulated with various agonists as described above.
doi:10.1371/journal.pone.0154342.g002
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explained by the decreased expression of receptors/subunits, as previously reported (CD42b
and CD49b; Fig 2b) [25, 35, 36]. In addition, the lower collagen response might also be due to a
defective GPVI signaling response, as GPVI is described as the major collagen receptor [37].
Interestingly, the expression of Clec2 was not decreased, and GPVI expression was only mini-
mally affected, which could therefore not explain the prominent reduction in aggregation
when stimulated with aggretin, convulxin or collagen, respectively.
Since GPVI and Clec2 receptors share Syk-dependent signaling pathways [38], we next
aimed at evaluating whether those responses are indeed Syk-dependent. In order to do that, we
generated Syk-lox|Pf4-Cre mice. From now on we refer to these mice as SykcKOMK, and to
control Syk-lox littermates as WTlox. We measured platelet aggregation using FCA as per-
formed above, and observed that upon stimulation with aggretin (Clec2), collagen (GPVI and
α2ß1, being GPVI the major collagen receptor) and convulxin (GPVI), platelet aggregation
responses were almost absent, while the aggregation response was normal when stimulated
with PMA (αIIbß3) and botrocetin (GPIb/V/IX; Fig 2c). This result corroborates the notion
that Clec2 and GPVI share Syk-dependent signaling pathways [38], and confirms the overlap
of Clec2- and GPVI-dependent responses with Gata1cKOMK platelets, which prompted us to
investigate whether Syk expression was affected in Gata1cKOMK mice.
Syk transcription is regulated by Gata1
To investigate if Syk transcription is affected in the megakaryocytic lineage of Gata1cKOMK
mice, mRNA and protein expression levels were measured in cultured sorted Gata1cKOMK
megakaryocytes and platelets, respectively (Fig 3a and 3b). A significant reduction in both Syk
mRNA and protein levels was observed, suggesting that Gata1 could regulate its expression.
We identified a WGATAR binding site 600bp upstream of the Syk gene start codon and per-
formed Gata1 ChIP experiments on WTlox and Gata1cKOMK megakaryocytes (as background
control) to elucidate whether Gata1 interacts directly with the Syk promoter.
We took as positive control a GATA positive (+) amplicon (-300bp) at the Gp1ba pro-
moter (known Gata1 target) and as a negative control a GATA negative (−) amplicon
(-600bp) at the Cd9 promoter. Gata1 ChIP results show enrichment at the GATA site in the
Syk promoter in WTlox megakaryocytes, similarly to the positive control, while it does not
enrich above background at the GATA negative (−) site in the Cd9 promoter (Fig 3c). There-
fore, this data corroborates the notion that Syk is a bona fide Gata1 target.
Aberrant megakaryocyte maturation in Gata1cKOMK mice
Megakaryocyte maturation was determined based on receptor expression profile in the bone
marrow and the spleen. Five consecutive stages (I-V) of megakaryocyte maturation could be
identified, as previously described, whereby subtype I contains the most immature and V the
most mature megakaryocytes (for gating strategy see Fig 4a) [31].
To validate the differentiation status of our megakaryocyte subpopulations based on flow
cytometry, the ploidy status of the individual subpopulations was analyzed. We observed a pos-
itive correlation of ploidy level with maturation progression following stages I to V, which in
our view validates this megakaryocyte differentiation gating strategy [31].
Compared to WTlox littermates, and as previously reported, we identified a shift towards
more immature megakaryocytes in the bone marrow, i.e. a relative increase in population I and
a decrease in populations IV-V (Fig 4b). Interestingly, we identified an additional subpopula-
tion exclusively in the Gata1cKOMK samples, indicated as II+, in which megakaryocytes with
low SSC characteristics express higher levels of CD61. In concordance with this, and similarly
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to what has been described in other Gata1 deficient mouse models, when analyzing the ploidy
status of CD41+ megakaryocytes in the bone marrow, we observed that there was an increase
of 2N megakaryocytes, and the normal 16N profile was lost (Fig 4c). Furthermore, ploidy anal-
ysis of the II+ population revealed that this population was composed of mainly of megakaryo-
cytes at 2N and 4N ploidy level, with a low percentage of 8N-16N, similarly to what we observe
in population II in WTlox samples, supporting the notion that the II+ population identified in
the Gata1cKOMK samples are megakaryocytes at stage II that start expressing higher (timely
inappropriate) levels of CD61 (Fig 4d).
In contrast to human, the mouse spleen is known to be a secondary hematopoietic organ for
megakaryopoiesis and erythropoiesis, whereby the output of erythroid cells and platelets
increases during stress hematopoiesis [39]. Although we did not notice a change in any of the
megakaryocyte progenitor subpopulations in the spleen, we did identify the II+ subpopulation,
comparable to the bone marrow (Fig 4b). However, we cannot conclude whether this aberrant
megakaryocytic stage is dependent on Gata1 loss, or a consequence of the thrombocytopenia
or stress megakaryopoiesis itself.
Fig 3. Gata1 regulates Syk expression. (a) Syk mRNA expression levels in Gata1cKOMK andWTlox
cultured megakaryocytes measured by qRT-PCR. (b) Syk protein levels in Gata1cKOMK andWTlox platelets,
analyzed byWestern blotting. Syk expression level normalized to loading control Gapdh is indicated, setting
the average expression levels of Syk in WTlox platelets to 100. (c) Chromatin immunoprecipitation (ChIP)
assay showsGata1 binding to the Syk promoter in WTlox compared to Gata1cKOMK (background control)
cultured megakaryocytes. A GATA positive (+) site on the promoter of the known targetGp1ba (CD42b) was
used as positive control and a GATA negative (−) site on the promoter of Cd9 was used as negative control.
doi:10.1371/journal.pone.0154342.g003
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Fig 4. Gata1cKOMKmice have a defect in megakaryopoiesis. (a) Gating strategy to identify megakaryocytes at consecutive stages of
differentiation in the bone marrow and the spleen based on surface marker expression CD31, CD61, CD41 and CD42b. The dot plot depicts the
extra population, named II+ found exclusively in Gata1cKOMK bone marrow. On the right we show the ploidy status of the individual
subpopulations, thereby justifying our gating strategy. (b) Percentage of megakaryocytes at consecutive stages of differentiation (I-V) of
nucleated bone marrow and spleen cells. (c) Ploidy staining of CD41-positive bone marrow and spleen megakaryocytes. The right bar graph
depicts ploidy staining of CD41+ in bone marrow. (d) Ploidy status of gated II+ megakaryocyte differentiation stage vs total CD41+ cells in two
representative Gata1cKOMK bone marrow samples.
doi:10.1371/journal.pone.0154342.g004
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Misbalance of multipotent progenitors in the bone marrow of
Gata1cKOMK mice
To investigate the repercussion of Gata1 deletion in megakaryocytes on the hematopoietic
compartment, we analyzed the distribution of hematopoietic progenitors in the bone marrow
based on receptor surface expression whereby nucleated, Lin-|Sca-1+|Kit+ cells were identified
as LSK and Lin-|Kit+|Sca-1- as multipotent progenitors (MP). A further subdivision of MPs
was made based on CD16/CD32 and CD34 expression, whereby we could differentiate between
the common myeloid progenitor (CMPs), granulocyte-macrophage progenitor (GMP) and
megakaryocyte-erythroid progenitor (MEP) (see Fig 5a for gating strategy).
This revealed that Gata1cKOMK mice display a misbalance in hematopoietic progenitors, i.
e. an increase in the total number of myeloid progenitors (MP). This increase is mainly due to
an increase in CMP cells at the expense of GMP and MEP cells (Fig 5b). This could be an indi-
rect effect of the chronic thrombocytopenia displayed by Gata1cKOMK mice, however, we
could not exclude other possibilities implicit to the genetic strategy as to affect the balance of
hematopoietic progenitors in our system. Severe thrombocytopenia is accompanied by a raise
in plasma thrombopoietin (TPO) levels, when the megakaryocyte-platelet mass is reduced, and
it is known that excess TPO has a direct effect on hematopoietic stem cells [40]. Contrary to
what could be anticipated, TPO plasma levels were mildly reduced in Gata1cKOMK as com-
pared to WTlox mice (Fig 5c). This suggests that despite the severe thrombocytopenia, the
megakaryocyte-platelet mass is increased, due to the overgrowth of immature megakaryocyte
populations identified in the bone marrow in Gata1cKOMK as compared to WTlox mice (Fig
4b). On the other hand, it has been reported that Pf4 produced by megakaryocytes in the bone
marrow niche affects hematopoietic stem cell quiescence and therefore performance [41], and
since Pf4 is a Gata1 target gene [25, 42], we aimed at analyzing Pf4 mRNA levels in bone mar-
row derived Gata1cKOMK megakaryocytes. As shown in Fig 5d, Pf4 was significantly, although
mildly, upregulated in Gata1cKOMK cultured megakaryocytes. Therefore, we can conclude that
Pf4 production is not deficient in these megakaryocytes.
Twinned compensatory stress erythropoiesis that accompanies the
stress megakaryopoiesis of Gata1cKOMK mice
As show in Fig 5, we identified alterations in the hematopoietic compartment, where we
noticed and increase in CMP and a decrease in GMPs and MEPs. Although the red blood cell
count in Gata1cKOMK mice was normal (Fig 1b), we were interested on the repercussion of the
defective platelet production on erythroid differentiation.
Based on surface expression of CD71 and Ter119, as described by Socolovsky et al [43], four
consecutive erythroid differentiation stages can be identified, whereby I is the most immature
erythroid progenitor and IV the most mature erythroid progenitor; addition of KIT to the
panel allows the detection of proerythroblasts, which are KIT+ CD71+ (for gating strategy see
Fig 6a). The bone marrow erythroid compartment showed a clear shift towards more mature
erythroid cells, i.e. in population IV and a decrease in the more immature erythroid popula-
tions, i.e. I-III (Fig 6b). The splenic erythroid compartment did not show overt changes in the
distribution of I-IV stages, although there was a tendency to an increase in mature erythroid
cells (stage IV, Fig 6c). However, and although the RBC counts were normal, these mice pres-
ent with splenomegaly. This suggests that there is compensatory extramedullary hematopoie-
sis/erythropoiesis, probably due to the indirect exhaustion in MEPs caused by the described
thrombocytopenia that suffer these mice (Fig 6d). Therefore, incapacitated megakaryopoiesis
on a chronic manner (stress megakaryopoiesis) due to Gata1 loss in mature megakaryocytes,
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Fig 5. Gata1cKOMKmice have a defect in the hematopoietic early precursor compartment (a) Flow cytometry analysis of the stem cell and
committed progenitor compartment. LSK, Lin-|Sca-1+|Kit+ cells; MP (Lin-|Sca-1-|Kit+), multipotent progenitors; CMP (MP gate—CD34+|CD16/
CD32mid), commonmyeloid progenitor; GMP (MP gate—CD34-|CD16/CD32+), granulocyte-monocyte progenitor; MEP (MP gate—CD34-|CD16/
CD32-), megakaryocyte-erythroid progenitor. (b) Percentage of the different hematopoietic progenitors. Absolute cell number of bone marrow
megakaryocytes at consecutive stages of differentiation [31]. The dot plot depicts the extra population, named II+ found exclusively in Gata1cKOMK
bone marrow. (c) Whisker/Box plot depicts plasma TPO levels from Gata1cKOMK andWTlox blood samples, as measured by ELISA. At least 5 mice
were analyzed per genotype. (d) qPCR analysis of Pf4 mRNA expression levels in cultured bone marrow derived Gata1cKOMK andWTlox
megakaryocytes.
doi:10.1371/journal.pone.0154342.g005
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Fig 6. Gata1cKOMKmice show alterations in the erythroid compartment. (a) Gating strategy to identify erythrocytes at consecutive stages of
differentiation in the bone marrow and the spleen based on surface marker expression KIT, CD71 and Ter119. (b) Percentage of reticulocytes at
consecutive stages of differentiation of live cells. Left graph depicts the bone marrow compartment, right the splenic compartment. (c) Photograph
of representative spleens from Gata1cKOMK and control mice shows the splenomegaly that Gata1cKOMKdevelop.
doi:10.1371/journal.pone.0154342.g006
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influences the early hematopoietic and erythroid compartments inducing compensatory extra-
medullary hematopoiesis/erythropoiesis.
Discussion
Gata1 is a key transcription factor involved in both erythroid and megakaryocyte development
and essential for terminal differentiation of these lineages. Since Gata1 knockout mice are lethal
due to severe anemia [22], different Gata1 targeted mouse models were generated to investigate
the role of Gata1 in adult mice, including ΔneoΔHS [2] and Gata1.05 mice [24]. Although
these models were fundamental in identifying the critical role of Gata1 in megakaryopoiesis,
they are not restricted to the megakaryocytic lineage or they pose a model for the downregula-
tion of the expression levels of Gata1 without gene ablation. Therefore, we generated Gata1-
lox|Pf4-Cre mice, since Pf4-Cre are a generally accepted Cre mouse model to induce megakar-
yocyte/platelet specific gene recombination [26], to investigate the function of Gata1 in mature
megakaryocytes. Previous reports have shown that this system could have some leakage in a
minor population of circulating leukocytes, a subset of monocytes and macrophages and in epi-
thelial cells of the colon; however, Gata1 is scarcely expressed in these cells, thus we exclude
major effects from recombination of Gata1 in these lineages [44, 45].
Comparable to the ΔneoΔHS and Gata1.05 mouse models, Gata1cKOMK mice show severe
macrothrombocytopenia accompanied by platelet dysfunction, while in Gata1cKOMK mice the
red blood cells and white blood cell counts are unaffected. Our platelet functionality tests
showed that our mouse model has similar platelet defects shown in previous Gata1 deficient
mouse models, including a defect in aggregation when platelets are stimulated with botrocetin
and collagen. This aggregation defect could be explained by the defective expression of respec-
tive receptors/subunits (i.e. vWF-R and CD49b). Besides these known platelet defects we show
that platelets from Gata1cKOMK mice have an aggregation defect when stimulated with aggre-
tin and convulxin. Since the defect could not be explained by downregulation of Clec2 or GPVI
receptor expression (or at least considering the extent of downregulation) on these platelets, we
next aimed at studying whether a common signaling protein, Syk, could be involved in the
lower response. In fact, FCA performed on SykcKOMK platelets confirmed an essential role of
Syk kinase on the platelet aggregation responses induced by aggretin, convulxin and collagen,
but not on those induced by PMA or botrocetin. In addition, pre-treatment of platelets from
WT animals with a Syk kinase inhibitor prior platelet aggregation induction results in the same
FCA profile when using the same battery of agonists, i.e. defective aggretin, convulxin and col-
lagen responses, normal PMA and botrocetin responses [29]. Syk, is essential during megakar-
yocyte migration and spreading and involved in platelet aggregation, and thus essential for
normal megakaryocyte function [46]. We therefore found it of relevance to study whether
Gata1 could be directly involved in the transcriptional regulation of Syk.
A reduced expression of Syk was noticed in mRNA of megakaryocytes and protein extracts
of platelets from Gata1cKOMK mice and we found that Gata1 directly regulates the transcrip-
tion of Syk by employing ChIP assays. These data support the notion that Syk is a direct Gata1
target in megakaryocytes and explain the GPVI/Clec2 dependent aggregation defects shown in
Gata1cKOMK platelets. The lowered, but not complete absence of this protein could be
explained by the fact that Gata1 recombination occurs in mature megakaryocytes, and we can-
not exclude the possibility that combinatorial interactions between several transcription factors
during megakaryopoiesis allows for basal transcription [12, 15, 18].
The severe thrombocytopenia caused a mild shift in megakaryocyte maturation in the bone
marrow compartment, which could be explained by the increased demand in output of plate-
lets. Interesting, however, is the new II+ population we identified in both the bone marrow and
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the splenic compartment. This SSClow CD61high population could be a consequence of the
increased pressure on megakaryocyte maturation. Of note, although the ploidy profile of this
II+ megakaryocyte population in Gata1cKOMK mice resembles mostly the WTlox II megakar-
yocyte ploidy profile, we have to consider that the 8N in the Gata1cKOMK megakaryocytes dis-
plays a characteristic double peak, which does not appear in WTlox samples.
Analysis of the hematopoietic precursor compartment revealed a shift in total number of
MPs, CMPs, GMPs and MEPs. The shift could potentially be explained by the severe and
chronic thrombocytopenia suffered by Gata1cKOMK mice; still we could not discard Gata1-de-
pendent or -independent alterations in relevant factors such as Pf4 or TPO to be causative of
the misbalance observed at the progenitor level. Thrombocytopenia is normally accompanied
by raised TPO levels (when the megakaryocyte-platelet mass is reduced), and it has been previ-
ously reported that besides a direct effect of TPO on megakaryocyte proliferation and matura-
tion, TPO also influences directly hematopoietic stem cell (HSC) quiescence and cycling [40,
47]. Contrary to what could be anticipated, TPO levels were mildly lower in Gata1cKOMK
mice. This supports the notion that despite the severe thrombocytopenia, the megakaryocyte-
platelet mass is increased due to the overgrowth of immature megakaryocytes. In concordance
with these results, it has been previously reported that Gata1-low mice display normal TPO
levels [48]. Reduction of MEPs could be a consequence of a higher demand of platelets, which
leads to exhaustion of the most committed progenitors towards the demanded lineage, through
TPO stimulation. In addition, we examined mRNA levels of Gata1-target Pf4 in bone marrow
derived cultured megakaryocytes, as it has been recently reported the important and local role
of this megakaryocyte-secreted factor on HSC senescence/performance [41]. Pf4 levels were
increased in Gata1cKOMK megakaryocytes. Interestingly, megakaryocytes from Gata1-low
mice have increased Pf4 levels [49], profile that is reversed (Gata1 increases and Pf4 decreases)
in Gata1-low mice treated with a TGFβ inhibitor. Furthermore, Gata1 timely represses Pf4 in
immature megakaryocytes in cooperation with Eto2 [42]. It is important to acknowledge the
complexity of Gata1 transcription regulation, which includes its participation in activating as
well as repressing transcription factor complexes, as it has been well characterized in the ery-
throid lineage [13, 50].
A closer look at the erythroid compartment, revealed a change in erythroid maturation in
the bone marrow and the spleen, and splenomegaly. Both organs showed an increased percent-
age of mature erythroid cells, which together with the splenomegaly, suggest compensatory
stress erythropoiesis or extramedullary hematopoiesis/erythropoiesis that develops as a direct
consequence of the (chronic) thrombocytopenia.
In summary, Gata1 loss in the megakaryocytic lineage leads to -chronic- thrombocytopenia
and dysfunctional platelets. The platelet dysfunction is a direct consequence of Gata1 loss,
since several receptors and signaling molecules are bona fide Gata1 targets, amongst which,
Syk is demonstrated in the present manuscript. Megakaryopoiesis in these mice do not follow
the normal paths, and Gata1 null megakaryocytes seem to proliferate rather than differentiate,
as has been previously suggested. In the present manuscript we identify an aberrant megakar-
yocyte differentiation stage, misbalance of hematopoietic precursor progenitors and extrame-
dullary hematopoiesis. We think that these latter events are a consequence of the -chronic-
thrombocytopenia, rather than Gata1 gene recombination in the megakaryocytic lineage itself.
However, whether these events occur only in the context of Gata1 loss or are merely due to the
severe prolonged thrombocytopenia (or both), needs to be further investigated. In particular,
whether a local recruitment of TPO or overproduction of Pf4 by immature megakaryocytes
would exert locally an effect on hematopoietic stem cells at the microenvironment level,
remains to be elucidated.
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